Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Care Publish Ahead of Print published online ahead of print December 27, 2007
DOI: 10.2337/dc07-1739

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-1739v1
31/3/442    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lopez, X.
Right arrow Articles by Goldfine, A. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lopez, X.
Right arrow Articles by Goldfine, A. B.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Human Insulin Analog Induced Lipoatrophy

Ximena Lopez, MD1,,3, Mariana Castells, MD2,,3, Alyne Ricker, MD1,,3, Elsa F. Velazquez, MD2,,3, Edward Mun, MD2,,3 and Allison B. Goldfine, MD1,,3

1Joslin Diabetes Center,
2Brigham and Woman's Hospital,
3Harvard Medical School, Boston, Massachusetts

Allison.Goldfine{at}Joslin.Harvard.Edu

ABSTRACT

Objective: To characterize pathophysiology of recombinant human insulin-induced lipoatrophy.

Research Design and Methods: We performed immunologic laboratory evaluation and skin testing for different insulin analogs and diluents in patients with type 1 diabetes and severe insulin-induced local lipoatrophy. Subcutaneous adipose tissue biopsies of areas of acute (7 days) and chronic insulin administration were examined. Topical sodium cromolyn was applied twice a day to atrophic areas and prophylactically to new sites of insulin administration.

Results: Subcutaneous adipose biopsies showed an elevated population of tryptase-positive, chymase-positive degranulated mast cells. Of 5 patients treated with topical sodium cromolyn, none had new lipoatrophic sites and 4 showed improvements in old lesions.

Conclusions: Tryptase positive/chymase postitive mast cells, known to be sensitive to sodium cromolyn, may contribute to the destructive immune process mediated in response to exogenous insulin. Mast cell stabilizing therapy with topical cromolyn may reverse early and prevent new lipoatrophic lesions.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.